1-(2,5-Dihydroxyphenyl)-3-hydroxybutan-1-one
1-(2,5-Dihydroxyphenyl)-3-hydroxybutan-1-one is an inhibitor of iNOS and COX-2. 1-(2,5-Dihydroxyphenyl)-3-hydroxybutan-1-one inhibits LPS-induced excessive production of NO and PGE2, as well as the mRNA expression of pro-inflammatory cytokines TNF-α, IL-1β, IL-6 and IL-12. 1-(2,5-Dihydroxyphenyl)-3-hydroxybutan-1-one can be used in inflammation-related research.
For research use only. We do not sell to patients.
- CAS No.: 1083202-40-7
- Formula: C10H12O4
- Molecular Weight:196.20
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
COX-2 |
iNOS |
TNF-α 12.5 μM (IC50) |
IL-1β 11.7 μM (IC50) |
IL-6 10.6 μM (IC50) |
IL-12 13.5 μM (IC50) |
In Vitro
1-(2,5-Dihydroxyphenyl)-3-hydroxybutan-1-one (compound 7) (2.5-20.0 μM; 12 h pretreatment followed by 18 h LPS co-treatment) inhibits LPS-induced nitrite production in RAW264.7 macrophages with an IC50 of 12.5 μM, and suppresses PGE2 production with an IC50 of 9.5 μM[1].
1-(2,5-Dihydroxyphenyl)-3-hydroxybutan-1-one (2.5-20.0 μM; 12 h pretreatment followed by 18 h LPS co-treatment) dose-dependently inhibits LPS-induced iNOS and COX-2 protein expression in RAW264.7 macrophages[1].
1-(2,5-Dihydroxyphenyl)-3-hydroxybutan-1-one (pretreated for 12 h, followed by co-treatment with LPS for 18 h) inhibits LPS-induced mRNA expression of TNF-α, IL-1β, IL-6 and IL-12 in RAW264.7 macrophages, with IC50 values of 12.5, 11.7, 10.6 and 13.5 μM, respectively[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:RAW264.7 macrophages
-
Concentration:2.5, 5, 10, 20 μM
-
Incubation Time:12 h pretreatment, followed by 18 h LPS co-treatment
-
Result:Attenuated LPS-induced iNOS and COX-2 protein expression in a dose-dependent manner.
Chemical Information
-
CAS No. 1083202-40-7
-
Molecular Weight 196.20
-
Formula C10H12O4
-
SMILES
OC1=CC=C(C=C1C(CC(C)O)=O)O
-
Structure Classification
-
Initial Source
Paraconiothyrium sp
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
RT-PCR
Reverse transcription technology uses RNA as a template to synthesize DNA. RT-PCR is simple, specific and sensitive, and can be used to detect gene expression levels and expression differences in cells; detect RNA virus content; clone cDNA sequences of specific genes.
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
LPS-Induced Endotoxemia/Systemic Inflammation
Lipopolysaccharide (LPS)-induced endotoxemia is a widely used in vivo model of acute systemic inflammation in which LPS, a Gram-negative bacterial endotoxin, activates innate immune signaling primarily through TLR4, leading to rapid and transient induction of pro-inflammatory cytokines such as TNF-α, IL-6, and IL-1β in circulation and tissues. This cytokine surge is commonly used as a measurable readout of systemic inflammatory activation and immune dysregulation, and is typically assessed within hours after intraperitoneal LPS administration in mouse models of endotoxemia. The model captures key features of systemic inflammatory response syndrome, including cytokine release, immune cell activation, and downstream tissue responses, and has been used to evaluate anti-inflammatory interventions such as cytokine modulation, lipid mediators, and immune cell-targeting therapies.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Real Time qPCR (Q-PCR)
Real-time quantitative PCR (qPCR) quantifies an amplifiable nucleic-acid target by monitoring fluorescence during PCR cycling rather than measuring product only after amplification. The increase in fluorescence tracks accumulation of PCR product, and the quantification cycle (Cq; historically also Ct/CP) is related to the initial amount of target: samples containing more starting target generally reach the defined fluorescence threshold in fewer cycles.
-
Pyroptosis Solutions
Pyroptosis is a lytic inflammatory cell-death pathway executed by gasdermin pores, most classically through inflammasome-mediated activation of caspase-1, cleavage of gasdermin D, membrane pore formation, LDH release, and secretion of IL-1β and IL-18. The canonical pathway is commonly modeled by priming cells with an inflammatory signal such as LPS to induce pro-IL-1β and inflammasome components, followed by an activation signal such as ATP or nigericin to activate NLRP3, ASC speck formation, caspase-1 cleavage, GSDMD cleavage, cytokine release, and pyroptotic membrane rupture. The non-canonical pathway is triggered when cytosolic LPS activates mouse caspase-11 or human caspase-4/5, leading to GSDMD cleavage and pyroptosis, and this can secondarily activate NLRP3-dependent IL-1β release. Pyroptosis is linked to inflammatory injury, infection, cancer, liver disease, ocular disease, placental inflammation, and other disease phenotypes, but unresolved questions include which gasdermin fam
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)